Related Experiment Video
Updated: Apr 28, 2026

Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles
Published on: August 2, 2016
pH- and reduction-responsive polymeric lipid vesicles for enhanced tumor cellular internalization and triggered drug
Sheng Wang1, Shuangnan Zhang, Junqing Liu
1Institute of Nanobiotechnology, School of Materials Science and Engineering, Tianjin University and Tianjin Key Laboratory of Composites and Functional Materials , Tianjin 300072, PR China.
Abstract:
Enhanced tumor cellular internalization and triggered drug release are two main concerns in the development of nanoparticles for antitumor drug delivery. In this article, a new kind of smart pH- and reduction-dual-responsive drug- loaded PEG coated polymeric lipid vesicle (PPLV) that can achieve both enhanced tumor cellular internalization and triggered drug release has been designed and prepared. The PPLVs were formed from amphiphilic dextran derivatives. The antitumor drug, doxorubicin (DOX), was loaded in the cores of the PPLVs. The newly developed PPLVs had a nanosized structure (∼40 nm) with PEG coating, so they were neutral and had high colloidal stability in the blood circulation. The in vitro physicochemical characterizations showed that the PPLVs lose their PEG coating and expose the positive surface charge under acidic environments. The in vitro cellular uptake study indicated that the acidic-treated PPLVs can efficiently enter tumor cells. It has been demonstrated by in vitro DOX release profiles that the PPLVs can achieve a triggered drug release in response to the reduction environment. The MTT assay demonstrated that DOX-loaded PPLVs treated with pH 5.0 solution had higher antitumor activity than DOX-loaded PPLVs treated with pH 7.4 solution. These results suggested that the PPLVs were promising nanoparticles for smart antitumor drug delivery applications.
More Related Videos
Related Concept Videos
Site-Targeted Drug Delivery Systems: Polymeric Carriers
Modified-Release Drug Delivery Systems: Site-Targeted
Modified-Release Drug Delivery Systems: Stimuli-Activated
Modified-Release Drug Delivery Systems: Classification
Modified-Release Drug Delivery Systems: Rate-Programmed II

